



Powered by



Curious About BioVentureHub *Community Members*



Henrik Klein Moberg,
CTO, Co-Founder, IFLAI

Curious About BioVentureHub Community Members

Meet Henrik Klein Moberg, CTO and Co-founder of IFLAI.

We had a talk about what drives him, the challenges they've faced, and why being part of BioVentureHub, so close to AstraZeneca, makes a real difference.

To start with - what is IFLAI and what do you do?

IFLAI is an emerging university spinoff company specializing in data- and energy-efficient AI for industrial applications. My primary mandate is to drive the company's technological development, focusing both on the design of the underlying AI architectures and their integration into customer workflows.

What inspired you to become an entrepreneur?

It was less a single moment and more a gradual realization during my PhD. I worked on using deep learning to extract weak signals from very noisy scientific data, and I saw that many valuable measurements already contain much more information than we normally manage to extract from them.

But for me, there was a clear disconnect between what was possible and what was actually made available in real laboratories, real workflows and real industries. The entrepreneurial part came from wanting my work to matter outside isolated papers or projects.

What has been the biggest personal or professional challenge in moving from academic research into building IFLAI, and what did you learn from it?

The biggest shift has been moving from the academic question "can this be shown?" to the company-building question "can this be made useful, reliable and understandable for someone else?". In research, novelty is often the central value. In a company, this is usually not the key point - the value is much more in clarity, robustness, timing, integration and trust.

I have learned that a technically impressive AI model is only one part of the solution. The harder and more important work is often to define the problem precisely, understand the data and the user context, identify failure modes, and build something that fits into a real workflow that people actually use every day. That has made me more practical, but also more careful.

What's one thing people often misunderstand about your field?

People often think of AI as something very general, almost magical, or mainly as chatbots and automation. In scientific and industrial settings, the most valuable AI is often much more specific: it helps extract structure from complex, noisy or high-dimensional data that would otherwise be difficult to interpret or make use of.

The difficult part is not simply training a model. It is understanding what the data actually represent, where the uncertainty comes from, how the model can fail, and how the result should be evaluated. In practice, good AI depends just as much on domain knowledge, careful problem formulation and validation as on the algorithm itself.

What's the most exciting thing happening in your company right now?

The most exciting part is that IFLAI has moved from a general promise of efficient AI into concrete applications with real users and real output. We are working on systems that take complex scientific, technical or operational data and turn it into something interpretable, reproducible and actionable and genuinely useful.

And just in the last few days, we have revealed a new family of models for high-throughput microscopy that outperform all existing models on public benchmarks, consuming over 2000 times less energy to train than the second best model.

How has being part of the BioVentureHub community influenced your journey?

BioVentureHub has been valuable because it places us close to the real questions, constraints and ambitions of life science. It is easy to develop (the wrong) AI methods in isolation, and one needs to understand how they can be useful in environments where data, regulation, collaboration and scientific validity all matter significantly.

The Hub also provides a community of people who are building companies in similar stages, translating science and working close to AstraZeneca and the broader life science ecosystem, and their practical perspective has been very useful and time-saving for us to hear. Also, it has been relatively easy to get in touch with the larger companies present in the Hub, which would otherwise likely have been a longer and more complicated process.

If you could give one piece of advice to your younger self, what would it be?

I would tell myself to expect everything to take significantly longer than one expects, often for reasons that are hard to foresee, and plan accordingly. One clear advice that has helped me is to generally target several approaches in parallel, rather than trying to strategically pick the "best" one.

I would also say: do not wait until everything is perfectly finished before discussing it with others. Many ideas only become clear when they meet reality, whether that is through experiments, collaborators, customers or criticism. The goal is not to be certain from the beginning, but to learn quickly without losing focus.

What mindset keeps you going when building a deeptech company takes longer, and is more uncertain, than expected?

The mindset is definitely patience without passivity. Deeptech often takes time because the uncertainty is very real - one struggles with technical uncertainty, data uncertainty, market uncertainty, regulatory and organisational uncertainty all at the same time.

But slow progress is not the same as no progress. Each good experiment, customer conversation, failed assumption or clarified use case removes uncertainty and makes the path more concrete. None of these are lost time - they are just another stepping stone on the long but gratifying path of following the purpose one has set out for oneself.

Thank you, Henrik, for sharing your journey and insights!

Curious About
Community Members



Powered by

